PhoreMost Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
32
- Latest Deal Type
-
2ndary - Private
- Investors
-
12
PhoreMost General Information
Description
Operator of a drug target identification and drug discovery company, intended to identify new targets or drugs for future therapy. The company's platform provides cryptic druggable sites in the human genome and directly links them to useful therapeutic functions in a live-cell context, and then uses these functionally validated protein fragments to inform the design of small molecule drugs with the same shape, enabling medical practitioners to continue the pipeline of highly validated first-in-class drug discovery programs for out-licensing to pharma.
Contact Information
Website
www.phoremost.comCorporate Office
- Moneta Building, B280
- Babraham Research Campus
- Cambridge CB22 3AT
- England, United Kingdom
Corporate Office
- Moneta Building, B280
- Babraham Research Campus
- Cambridge CB22 3AT
- England, United Kingdom
PhoreMost Timeline
PhoreMost Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Secondary Transaction - Private | 01-Feb-2026 | Completed | Pre-Clinical Trials | |||
| 8. Later Stage VC (Series B) | 10-Sep-2024 | Completed | Pre-Clinical Trials | |||
| 7. Later Stage VC | 01-Jan-2021 | Completed | Pre-Clinical Trials | |||
| 6. Early Stage VC (Series A) | 30-Apr-2018 | Completed | Pre-Clinical Trials | |||
| 5. Grant | 27-Apr-2018 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC | 03-Mar-2017 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 13-May-2015 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 11-Mar-2015 | $6.12M | $6.12M | Completed | Pre-Clinical Trials | |
| 1. University Spin-Out | 01-Apr-2014 | Completed | Startup |
PhoreMost Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| A1 Ordinary | ||||||||
| A Ordinary | ||||||||
| A Ordinary | ||||||||
| A Ordinary | 46,700 | $0.001307 | $55.95 | $55.95 | 1x | $55.95 | 7.83% | |
| A Ordinary | 65,311 | $0.001307 | $50.81 | $50.81 | 1x | $50.81 | 10.96% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
PhoreMost Comparisons
Industry
Financing
Details
PhoreMost Competitors (70)
One of PhoreMost’s 70 competitors is Ncardia, a Venture Capital-Backed company based in Leiden, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ncardia | Venture Capital-Backed | Leiden, Netherlands | ||||
| Integral Molecular | Private Debt Financed | Philadelphia, PA | ||||
| Virometix | Venture Capital-Backed | Schlieren, Switzerland | ||||
| Circle Pharma | Venture Capital-Backed | South San Francisco, CA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
PhoreMost Patents
PhoreMost Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202510328-D0 | Small molecule and applications of the same | Pending | 27-Jun-2025 | ||
| GB-202407128-D0 | Methods of protein engineering and functional screening | Inactive | 20-May-2024 | ||
| GB-202319002-D0 | Methods of protein engineering and functional screening | Inactive | 13-Dec-2023 | ||
| EP-4784781-A1 | Methods of protein engineering and functional screening | Pending | 28-Sep-2023 | ||
| GB-202314894-D0 | Methods of protein engineering and functional screening | Inactive | 28-Sep-2023 |
PhoreMost Signals
PhoreMost Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 5Y Capital | Venture Capital | Minority | ||
| Astellas Venture Management | Corporate Venture Capital | Minority | ||
| Meltwind Advisory | Venture Capital | Minority | ||
| Trend Investment Group | Venture Capital | Minority | ||
| XtalPi Technology | Corporation | Minority |
PhoreMost FAQs
-
When was PhoreMost founded?
PhoreMost was founded in 2014.
-
Where is PhoreMost headquartered?
PhoreMost is headquartered in Cambridge, United Kingdom.
-
What is the size of PhoreMost?
PhoreMost has 32 total employees.
-
What industry is PhoreMost in?
PhoreMost’s primary industry is Drug Discovery.
-
Is PhoreMost a private or public company?
PhoreMost is a Private company.
-
What is PhoreMost’s current revenue?
The current revenue for PhoreMost is .
-
How much funding has PhoreMost raised over time?
PhoreMost has raised $83M.
-
Who are PhoreMost’s investors?
5Y Capital, Astellas Venture Management, Meltwind Advisory, Trend Investment Group, and XtalPi Technology are 5 of 12 investors who have invested in PhoreMost.
-
Who are PhoreMost’s competitors?
Ncardia, Integral Molecular, Virometix, Circle Pharma, and CytomX Therapeutics are some of the 70 competitors of PhoreMost.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process